Pacira Pharma (PCRX) Posts Wider than Expected Loss; Reiterates FY11 Outlook

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q1 loss of $0.98, $0.45 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $4.16 million.

Reiterates FY11 revs outlook.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15